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locus variable-number tandem repeat analysis
Cyril Férandon1,2†, Olivia Peuchant1,2,3†, Hélène Renaudin3 and Cécile Bébéar1,2,3*Abstract
Background: Mycoplasma hominis is an opportunistic human mycoplasma species that can cause various
urogenital infections and, less frequently, extragenital infections. The objective of this work was to study the genetic
diversity of this species using a molecular typing method based on multiple-locus variable-number tandem repeat
(VNTR) analysis (MLVA).
Results: The genome content of M. hominis PG21 was analysed for tandem repeats (TRs), and five of the 130 TRs
identified were selected for use in an MLVA assay. The method was based on GeneScan analysis of VNTR loci using
multiplex PCR with fluorescent dyes and resolution by capillary electrophoresis. This approach was used on a
collection of 210 urogenital and extragenital French clinical isolates collected between 1987 and 2009. Forty MLVA
types were found. The discriminatory index of our MLVA scheme was 0.924. Using this new typing tool, persistent
infection was suggested for six patients and new infection for one patient. Furthermore, mother-to-child
transmission was confirmed in the two cases studied. Application of MLVA to a wide range of M. hominis isolates
revealed high genotypic diversity and no obvious link between the MLVA type and the isolate year of collection,
the patient’s age or sex, the anatomical origin of the isolates or resistance to antibiotics was found.
Conclusions: Our MLVA scheme highlights the high genetic heterogeneity of the M. hominis species. It seems too
discriminatory to be used for large epidemiological studies but has proven its usefulness for molecular studies at
the individual level.
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Mycoplasma hominis is an opportunistic human myco-
plasma species that resides in the lower urogenital tract
as a commensal pathogen. This species has been impli-
cated in bacterial vaginosis (BV), pelvic inflammatory
disease, infection during pregnancy, preterm labour and
neonatal infections [1]. The occurrence of M. hominis
organisms in a large number in the vagina and cervix is
recognized as being associated strongly with BV. M.
hominis organisms and other BV-associated bacteria in* Correspondence: cecile.bebear@u-bordeaux2.fr
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reproduction in any medium, provided the orthe vaginal and cervical specimens, quite frequently
invaded the endometrium sometimes with an antibody
response [2,3]. M. hominis has been isolated from the
endometria and fallopian tubes of about 10% of women
with salpingitis at laparoscopy and accompanied by spe-
cific antibodies [4]. More recently, Taylor-Robinson
et al. reported that of 22 women with salpingitis at
laparoscopy, M. hominis was a questionable sole cause
in one woman and the primary or equal primary con-
tributor in three [3]. In this study, M. hominis in a large
number (≥ 104-105 color changing units -CCU- /ml) in
the vagina and cervix were detected most often in
women with salpingitis at laparoscopy. However, the sig-
nificance of this mycoplasma, especially when associated
with BV, can be difficult to assess when several microor-
ganisms are present [3,5]. Otherwise, M. hominis has
been linked to a variety of extragenital infections, suchral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and perirenal abscesses, mediastinistis and other infec-
tions in immunocompromised patients [5]. Any assess-
ment of the pathogenic potential of M. hominis is
complicated by the high degree of genomic and anti-
genic heterogeneity observed within the species.
A few molecular typing methods have been developed
for M. hominis. Pulse-field gel electrophoresis (PFGE)
[6,7], restriction fragment length polymorphism (RFLP)
analysis [8], amplified fragment length polymorphism
(AFLP) [9] and random amplified polymorphic DNA
(RADP) [10] have been used to study the genetic diversity
of this species. However, these methods are time-
consuming, require a relatively large amount of biological
material, may be difficult to reproduce and standardise
between laboratories and generate results that are difficult
to interpret.
Other molecular typing methods based on sequence
analyses of the p75, p120’ and vaa genes have been
developed [11-13]. An MLST approach based on the se-
quence analysis of six housekeeping genes and one gene
encoding a membrane protein was conducted for 20M.
hominis isolates [14]. However, this method was used to
estimate the frequency of recombination in M. hominis,
rather than for genotyping.
Multiple locus variable-number tandem-repeat
(VNTR) analysis (MLVA) is new genotyping method
based on the variation in the copy numbers of tandem
repeat (TR) sequences at different genomic loci among
isolates. MLVA has been used successfully to subtype
certain Mycoplasma species [15-19].
Using the recently described M. hominis PG21 genome
sequence [20], we developed an automated MLVA
scheme, without a sequencing step, for M. hominis typ-
ing. This method was subsequently applied to a wide
range of M. hominis clinical isolates from genital and
extragenital infections collected between 1987 and 2009.
We used MLVA to assess M. hominis genotypic diversity
and characterise the pattern of human infections.
Methods
Ethics statement
The present project is in compliance with the Helsinki
Declaration (Ethical Principles for Medical Research
Involving Human Subjects).
The study was conducted in accordance with the
guidelines of the “Direction de la Recherche Clinique et
de l’Innovation”, the research board of Bordeaux Univer-
sity hospital, Bordeaux, France. All patient data were
anonymously reported, with no possibility of connecting
the isolates and specimens to individual patients. Using
the written “livret d’accueil” of the Bordeaux University
Hospital, patients are explicitly informed at the admis-
sion to hospital that their samples could be used forresearch purposes and that they can oppose to this use.
As specimens used in this study are part of routine pa-
tient management without any additional sampling, and
since patients provided no objection for their samples to
be used, the article L1211-2 of the French code of Public
Health states that this study did not need to be exam-
ined by the ethical committee “Comité de Protection des
Personnes” and that patient’s informed consent was not
required.
Bacterial strains, culture and DNA preparation
The PG21 (ATCC 23114), M132 (ATCC 43521) and
H34 (ATCC 15056) M. hominis reference strains and
207 French clinical isolates collected between 1987 and
2009 were used in this study (Additional file 1: Table
S1). The 167 urogenital clinical isolates were collected at
the Bordeaux University Hospital and obtained from i)
specimens where M. hominis was present as a com-
mensal, i.e. cervical samples with titres of M. hominis <
104 CCU /ml and male specimens, ii) cervical swabs
from patients with titres of M. hominis ≥ 104 CCU /ml
without association with BV, iii) cervical swabs from
female patients with titres of M. hominis ≥ 104 CCU /ml
and suffering from bacterial vaginosis, iv) vaginal swabs
from pregnant women with threatened preterm delivery
whatever the titre of M. hominis, v) specimens from
women presenting upper genital tract infection whatever
the titre of M. hominis, these specimens being normally
sterile. Thirty-four isolates obtained from extragenital
specimens and collected at hospitals from 10 different
French cities were also tested. Finally, we genotyped six
isolates obtained from two mother-neonate pairs.
Among these 210 isolates, concomitant and sequential
isolates were obtained for one and seven patients,
respectively.
Antibiotic susceptibility testing, realised when M.
hominis was in a pathogenic situation, showed that 66
urogenital isolates were resistant to tetracyclines, seven
extragenital isolates were resistant to ofloxacin, two uro-
genital isolates were resistant to both tetracyclines and
ofloxacin and 91 isolates presented a wild-type profile.
The growth conditions used for the M. hominis iso-
lates have been described previously [21]. The DNA was
extracted using the MagNA Pure LC DNA isolation kit I
(Roche, Meylan, France) according to the manufacturer’s
instructions.
MLVA analysis
Tandem repeat (TR) sequences were identified in the M.
hominis PG21 genome [20] using the Tandem Repeats
Finder programme (http://tandem.bu.edu/trf/trf.html)
[22]. Loci were chosen if they had >80% matches be-
tween the DNA sequences of the repeat units. A total of
130 TRs were selected and designated by the letters
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in which the TR was detected. To screen for variability
in the number of TRs, PCR primers targeting the re-
gions flanking TR loci were designed and tested on a set
of 12M. hominis isolates, including the PG21, M132 and
H34 references strains, three urogenital isolates, one
from amniotic fluid, one isolate from peritoneal fluid,
one from joint fluid, one from bronchial aspirate, one
from abdominal wall abscess and one from a renal ab-
scess, collected between 1995 to 2008 from different
geographical areas (Additional file 1: Table S1). Each
locus was amplified individually and analysed by conven-
tional agarose gel electrophoresis.
To confirm that length polymorphisms were the result
of repeat copy number variations, the PCR products
were purified using the Wizard PCR Preps DNA Purifi-
cation System (Promega, Charbonnières-les-Bains,
France) and double-strand sequenced (Additional file 2:
Figure S1). This approach showed that only seven loci
were polymorphic with different allele sizes. After evalu-
ation of a large collection of M. hominis isolates, two of
these seven VNTRs were rejected due to a lack of ad-
equate discrimination, and the five remaining VNTR loci
were chosen for further assessment.
The five VNTR markers ultimately selected for use in
MLVA were multiplexed in two solutions named T1 and
T2. The markers Mho-50, Mho-52 and Mho-53 were
amplified using the solution T1, and the markers Mho-
114 and Mho-116 were amplified using the solution T2.
The amplifications were performed with a Mastercycler
ep Gradient S thermocycler (Eppendorf, Hamburg,
Germany) in a final volume of 25 μl. The reaction mix-
tures contained 1X Qiagen PCR buffer with 1.5 mM
MgCl2, 0.2 mM deoxynucleotide triphosphate, 3 mM
MgCl2, 0.625 U of Hot Start Taq DNA polymerase
(Qiagen, Hilden, Germany), 0.125 μM of each primer
and 1 μl of template DNA from clinical isolates. The for-
ward primers were fluorescently labelled at the 5’ end
using 4,4,7,2’,4’,5’,7’-hexachloro-6-carboxy-fluorescein
(HEX), 6-carboxyfluorescein (FAM; Eurogentec, Angers,
France) or NED (2’-chloro-5’-fluoro-7’,8’-fused phenyl-1,
4-dichloro-6-carboxyfluorescein; Applied Biosystems,
Life Technologies, Carlsbad, CA, USA), depending on
the locus to be amplified (Additional file 3: Table S2).
All of the solutions were run under the same cycling
conditions: 95°C for 15 min followed by 25 cycles of 95°C
for 1 min, 56°C for 1 min and 72°C for 1 min with a
final extension at 72°C for 10 min. Prior to GeneScan
analysis, 0.3 μl of GeneScan ROX 500 size standard (Ap-
plied Biosystems) was added to 1 μl of each PCR prod-
uct. After heat denaturation for 5 min at 95°C, the
fragments were separated using an ABI 3130 Genetic
Analyzer (Applied Biosystems). The GeneScan data
were subsequently analysed using GeneMapper software(version 3.7; Applied Biosystems) to perform sizing and
to calculate the number of repeats in the PCR fragments.
Each locus was identified according to colour fluores-
cence. An allele number string based on the number of
repeats at each locus was assigned to each isolate.
Data analysis
The calculated numbers of repeats were imported into
BioNumerics (version 6.1; Applied Maths). A minimum
spanning tree (MST) was generated to visualise the rela-
tionships between the large number of isolates in a sin-
gle compact image. The MST was created based on the
categorical coefficient and a priority rule consisting of
the highest number of single-locus variants. The poly-
morphism index of individual or combined VNTRs was
calculated using the Hunter-Gaston discriminatory index
(HGDI) [23].
Results
Identification of VNTRs for MLVA typing
Among the 130 TRs tested, only five were polymorphic
with different allele sizes, making them useful for dis-
criminating among types. The five VNTRs selected are
distributed around the genome from nucleotide posi-
tions 181200 to 298794 in the M. hominis PG21 refer-
ence strain (Table 1). The PCR products ranged in size
from 153 to 290 bp in the M. hominis PG21 reference
strain. All of the VNTRs were located in open reading
frames (ORFs). Markers Mho-52, Mho-53 and Mho-116
were located in the rpoD gene encoding the RNA poly-
merase sigma factor RpoD, the pgsA gene encoding the
CDP-diacylglycerol-glycerol-3-phosphate-3-phosphatidyl
transferase and the oppA gene encoding the oligopeptide
ABC transporter substrate-binding protein, respectively.
The two other markers were located in ORFs encoding
hypothetical proteins. The sizes of the unit repeats
ranged from 3 bp to 42 bp. Sequencing the PCR prod-
ucts of different sizes at each of the five loci from each
of the 12 screening isolates confirmed the sizes and se-
quences of the individual VNTR loci.
The stability of the five polymorphic markers in five
strains was examined after 10 serial passages in Hayflick
modified broth medium supplemented with arginine.
The analysis of the five strains resulted in identical
MLVA profiles for all markers.
The use of fluorescently labelled primers in two multi-
plex PCRs (Mho-50, Mho-52 and Mho-53 for PCR T1
and Mho-114 and Mho-116 for the PCR T2), and capil-
lary electrophoresis facilitated the interpretation of the
results, an improvement over the standard agarose gel
electrophoresis. Using GeneMapper Software, all loci
were clearly identified on electropherograms according
to their size ranges and colours, and the amplicon sizes
allowed the determination of repeat number.











































oppA gene (MHO_1510) 3 GAA 100 0.020
aPosition (5’ end) on the M. hominis PG21 genome sequence.
bHGDI, Hunter Gaston Diversity Index.
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The set of five VNTRs was used to type a large collec-
tion of 210M. hominis French clinical isolates. All of the
VNTRs were efficiently amplified in each M. hominis
isolate tested. The size variation of the amplicons was
exact multiples of the repeats (Table 2). This was con-
firmed by sequencing amplicons which presented an
unexpected size variation using the capillary electro-
phoresis analysis. The marker Mho-53 was the most
discriminatory VNTR, displaying six different allele
sizes with repeat copy numbers ranging from 3 to 8,
depending on the isolate. The markers Mho-50 and
Mho-52 showed five and three different allele sizes,
respectively. The other markers yielded only two
different-sized PCR products. The marker Mho-116
was the most homogenous marker, as almost all of the
isolates harboured one repeat (three harboured two
copies). This finding was reflected by the diversity
index of each VNTR, estimated from the HGDI, with a
value of 0.784 for the most discriminatory marker
(Mho-53) and a value of 0.020 for the less discrimin-
atory one (Mho-116). The overall discriminatory index
of the MLVA assay was 0.924.
A combined analysis of the five VNTR loci in the 210
M. hominis isolates revealed 40 MLVA types (Table 2).
Three MLVA types, 5, 8 and 10, were present in more
than 20 isolates. In 18 cases, one unique MLVA type was
observed in a single patient.
Interestingly, the two ATCC strains, H34 and M132,
had the identical MLVA type 10, while the PG21 ATCC
strain belonged to the MLVA type 36. The 167 uro-
genital isolates were classified into 34 MLVA types
(Additional file 1: Table S1). The 34 extragenital isolates
contained 14 MLVA types, including eight MLVA types
that had already been described for urogenital isolates.
One set of two concomitant extragenital isolates (Mh-
2537, Mh-2539) collected from the same patient wasanalysed. The MLVA typing led to an identical MLVA
profile for both isolates (Additional file 1: Table S1). Se-
quential isolates (obtained on time intervals from one
week to six months) from each of seven patients re-
vealed no intra-individual variation in six of them,
suggesting that they suffered from a persistent M.
hominis infection. For the seventh patient, the first iso-
late (Mh-4642) from the cervix was of MLVA type 2,
while the second cervical isolate (Mh-4724), obtained
three months later, belonged to the MLVA type 8, which
suggests a novel M. hominis infection.
Isolates collected from two mother-neonate pairs were
also analysed (Additional file 1: Table S1). In the first
case, isolates obtained from the bloodstream of the
mother and her new born infant belonged to the same
MLVA type 8. In the second case, isolates obtained from
the blood culture and cervix of the mother yielded the
MLVA type 7, as well as isolates collected from blood
culture and throat sample of her neonate.
The genetic relationships of the 210 isolates were de-
duced by construction of an MST (Figure 1). This popu-
lation model highlighted one major clonal complex,
composed of 207 isolates belonged to 38 MLVA types. A
second clonal complex could be defined for one urogeni-
tal isolate (Mh-3560) collected in 2003 and yielding the
MLVA type 24. A third clonal complex was represented
by two respiratory isolates (Mh-2327, Mh-2477) col-
lected six months apart in 1996–1997 from the same pa-
tient and were of the MLVA type 33. Interestingly, the
two VNTRs that were not used for the MLVA assay (due
to lack of discrimination) presented size variation only
with these two isolates and harboured identical TR num-
bers between both isolates. The MST population model-
ling indicated the genetic diversity among the isolates
tested. Unfortunately, there was no obvious link between
the MLVA type and the isolate year of collection, the
patient’s age or sex, the anatomical site of collection, or




No. of repeats at the following VNTR loci
Mho-50 Mho-52 Mho-53 Mho-114 Mho-116
1 1 8 8 1 1
2 1 8 3 1 1
3 1 8 3 2 1
4 1 8 4 1 1
5 1 8 4 2 1
6 1 8 4 2 2
7 1 8 5 1 1
8 1 8 5 2 1
9 1 8 6 1 1
10 1 8 6 2 1
11 1 8 7 1 1
12 1 8 7 2 1
13 1 8 8 2 1
14 3 8 3 1 1
15 1 9 3 2 1
16 1 9 4 1 1
17 1 9 4 2 1
18 1 9 5 2 1
19 2 8 3 1 1
20 2 8 3 2 1
21 2 8 4 1 1
22 2 8 4 2 1
23 2 8 5 2 1
24 2 9 7 1 1
25 3 8 3 2 1
26 3 8 4 1 1
27 3 8 4 2 1
28 3 8 5 2 1
29 3 8 6 2 1
30 3 8 7 2 1
31 3 9 4 2 1
32 3 9 7 2 1
33 4 8 3 2 2
34 4 8 4 2 1
35 4 8 5 2 1
36 4 8 6 2 1
37 5 8 4 2 1
38 1 10 3 2 1
39 1 10 4 2 1
40 1 10 5 2 1
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ofloxacin-resistant isolates were dispersed into 25 MLVA
types (Figure 1). It should be noted that no significant
difference in the repartition of MLVA types was identi-
fied between M. hominis cervical isolates present in ≥
104 CCU /ml in patients without BV and in patients with
BV (Additional file 1: Table S1).
Discussion
In this study, we present an MLVA-based molecular typ-
ing system for the discrimination of M. hominis isolates.
We used this method on a group of 210 temporally sep-
arated isolates from French patients and obtained from a
variety of urogenital and extragenital clinical circum-
stances. This effort represents the most comprehensive
M. hominis molecular typing study because, until now,
other studies were realised only on urogenital isolates
and few isolates were tested [7-10].
MLVA typing of M. hominis is important both indi-
vidually and epidemiologically. At the level of an individ-
ual patient, this approach allows discrimination between
relapse or persistence and new infections. In the first
case, the MLVA type remains identical. In the case of a
reinfection, the MLVA type is likely to be different. Our
MLVA scheme was used to study the course of infection
in seven patients. In six of these patients, sequential iso-
lates belonged to a consistent MLVA type in each case
studied, suggesting in a persistent or relapse infection.
Interestingly, the two clinical isolates Mh-2377 and Mh-
2477 harboured the unique MLVA type 33 whereas pre-
vious PFGE analysis showed different migrations pat-
terns when evaluated according to the interpretation
guidelines of Tenover et al., and the total genome sizes
of the two strains, deduced from the addition of the gen-
erated fragment lengths, were nearly identical [24].
These respiratory isolates were collected six months
apart from a man with a chronic obstructive pulmonary
disease who was treated several times with ciprofloxacin.
As the M. hominis isolates were both resistant to
fluoroquinolones, it would seem logical that the two iso-
lates were identical, as shown by MLVA typing. The ob-
served differences in PFGE patterns may be due to
restriction sites located in variable regions or to recom-
bination. Indeed, results from previous analysis indicated
that a high levels of intragenic and intergenic recombin-
ation occurred in M. hominis, and these recombination
levels are presumably important for the adaptation po-
tential of this species [11,14].
Analysis of our results suggests a new infection in a fe-
male patient, as the two sequential cervical isolates were
of different MLVA types. A previous study investigated
cervical isolates of M. hominis obtained before and after
treatment by RAPD. In two of nine cases studied, the








































Figure 1 Minimum spanning tree of 210M. hominis isolates based on categorical analysis of five VNTRs. Each circle represents a unique
MLVA profile, as indicated by a number. The size of each circle is proportional to the number of isolates belonging to the indicated MLVA type.
Thick connecting lines represent one marker difference. Regular connecting lines represent two marker differences. MLVA types connected by a
same background could be considered a clonal complex. Asterisks in the MLVA types indicate the presence of tetracycline-and/or
ofloxacin-resistant isolates.
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that the patients were reinfected [10].
We also performed molecular investigations of M.
hominis isolates from two mother-neonate pairs. In each
case studied, an identical MLVA type was found,
confirming mother-to-child transmission. Our results
are in agreement with those of Jensen et al. who
reported that M. hominis isolates obtained from the cer-
vices of pregnant women and from the ears or pharynges
of their new-born infants yielded the same genomic pro-
file by PFGE [7]. Similar results were obtained by
Grattard et al., who showed that strains isolated within a
mother-neonate pair exhibited an identical pattern by
AP-PCR [25].
At the population level, MLVA typing assesses the
genetic diversity of M. hominis strains. In this study, we
described 40 MLVA types, revealing a genetic heterogen-
eity among this species. This finding is in agreement
with the data obtained by studies using other molecular
typing methods. Using RFLP, Busch et al. found a highheterogeneity among 20 isolates obtained from colonised
women and women with various urogenital infections
[8]. The results from an AFLP analysis of five randomly
chosen clinical isolates also provided further evidence of
high-level intraspecies variability in this organism [9].
Soroka et al. reported genetic heterogeneity of genomes
of M. hominis isolates using RAPD, and their results
were confirmed by PFGE [10]. In comparison to the mo-
lecular typing methods that the other studies have used,
MLVA is a reproducible and fast technique that does not
require a sequencing step and can be standardised, facili-
tating large-scale molecular epidemiological investiga-
tions. The capillary electrophoresis on a genetic analyser
enables high throughput analysis and allows easier inter-
pretation of results (in contrast to agarose gel electro-
phoresis), particularly for VNTRs with a small number
of repeat units.
In M. hominis, a high level of resistance to tetracy-
clines has been associated with the presence of the
tet(M) determinant, the sole tetracycline resistance
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plasmas [26]. It has been reported that in Bordeaux,
France, the percentage of M. hominis isolates resistant to
tetracyclines increased significantly, from 2.8% to
18.75%, between 1999 and 2002 [27]. In our study, the
68 urogenital M. hominis isolates resistant to tetracy-
clines were not related and clustered into 25 MLVA
types, suggesting the absence of a link between tetracyc-
line resistance and this typing method. Our results are
in agreement with those of Mardassi et al., who recently
showed that resistance rates to tetracyclines were 25%
among Tunisian M. hominis isolates and that molecular
typing based on the nucleotide sequences of P120’ gene
fragments indicated that these isolates were not clonal [28].
Conclusions
This study represents the first attempt to perform mo-
lecular typing of a consequential number of M. hominis
clinical isolates using the MLVA method. The VNTR
analysis provides a rapid, simple molecular typing tech-
nique that has demonstrated its usefulness at the indi-
vidual level. This new typing tool revealed a high genetic
heterogeneity among M. hominis isolates, and seems too
discriminatory to be used for epidemiological studies at
a population level.
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